Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (August 2018)
25 slides from Genetic Signatures's investor presentation, Aug 15, 2018
Slide 1: Investor Presentation August 2018
ASX: GSS INVESTOR PRESENTATION AUGUST 2018 Genetic Signatures Limited Investor Presentation – August 2018
Slide 2: Disclaimer
Disclaimer This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange
Slide 3: Corporate summary
Corporate summary REVENUE STAGE HEALTHCARE COMPANY LISTED ON THE ASX Genetic Signatures Limited (ASX: GSS) Share price (A$) Volume (m) A specialist molecular diagnostics company 0.7 0.7 ― Focused on becoming a global leader in the 0.6 0.6 supply of molecular diagnostic solutions 0.5 0.5 ― Developing
Slide 4: GSS snapshot
GSS snapshot GENETIC SIGNATURES DEVELOPS AND MANUFACTURES MOLECULAR DIAGNOSTICS KITS BASED ON ITS PROPRIETARY 3BASETM TECHNOLOGY Established Strong portfolio revenues growth Track record of Substantial product revenues de-risks growth with 5 development and products expected sales expansion by end o
Slide 5: The science behind 3base technology
The science behind 3baseTM technology 3BASETM TECHNOLOGY REDUCES COMPLEXITY IN GENETIC TESTING ALLOWS TESTING FOR MORE DISEASES WITH HIGHER ACCURACY MORE RESULTS, MORE ACCURACY, LOWER COST 3baseTM technology 3baseTM technology in the detection process ― 3baseTM platform technology converts original
Slide 6: Powerful evidence of efficacy from clinical trials
Powerful evidence of efficacy from clinical trials Clinical trials demonstrate efficacy St Vincent’s Hospital Evaluation Study results Evaluation study conducted at St Vincent’s Pathogen Conventional EasyScreen™ Hospital, Sydney Methods* Campylobacter 7 9 221 patient samples tested and compared to t
Slide 7: EasyScreen products built on 3base technology
EasyScreenTM products built on 3baseTM technology GSS is commercialising a range of MDx tests based on 3baseTM and branded as EasyScreenTM EasyScreenTM kits offer faster and more effective detection of infectious disease ✓ Four product families available ✓ Common Workflow – all tests work under cove
Slide 8: The EasyScreen competitive advantage
The EasyScreenTM competitive advantage EASYSCREENTM KITS OFFER FASTER AND MORE EFFECTIVE DETECTION OF INFECTIOUS DISEASE; OPTIMISED FOR HIGH THROUGHPUT LABS High throughput Ability to test multiple samples simultaneously maximises pathogen testing capacity 200+ samples every 4-5 hours High specifici
Slide 9: Q4 FY18 trading update
Q4 FY18 trading update INTERNATIONAL EXPANSION GAINING MOMENTUM Q4 FY18 Revenue Update Quarterly revenue (A$000) ✓ Strong quarterly revenue 754 +20% 714 growth to A$691k in Q4 FY18, 677 on pcp 691 a +20% increase on pcp 575 ✓ First sales in the US 540 495 463 460 Q4 performance continues 442 410 423
Slide 10: Key corporate and operational milestones achieved
Key corporate and operational milestones achieved GSS HAS MADE STRONG PROGRESS OVER THE LAST 18 MONTHS Successful clinical trial results for Flavivirus Detection Kits at prestigious European conference in April 2017 TGA and CE-IVD Mark approvals received for the entire Enteric product suite by June
Slide 11: Strategy for FY19
Strategy for FY19 GENETIC SIGNATURES HAS A CLEAR FOCUS ON REVENUE GROWTH IN FY19 DRIVEN BY ITS INTERNATIONAL EXPANSION AND NEW PRODUCT RELEASES Roll-out of ― Current expectations of 5 product groups to be expanded approved in the near term across target regions product suite ― Continued progress wit
Slide 12: Executing a global strategy for commercialisation
Executing a global strategy for commercialisation MULTIPLE TRIALS UNDERWAY IN THE US, EUROPE AND AUSTRALIA 2 Europe: Rapidly increasing footprint to be ready for product approvals Trials underway ✓ Distributors appointed (Italy, Israel, Ireland and Poland) ✓ CE-IVD approvals granted for enteric and
Slide 13: Board of Directors have a track record of success
Board of Directors have a track record of success Tony Radford Non executive Director • Significant sales experience • Co-Founder and CEO of Cellestis until acquired by Qiagen for c.A$400m • Proven track record of executing a sales strategy into Europe Phillip Isaacs Non executive director Michael A
Slide 14: Australia: continue rapid growth
1 Australia: continue rapid growth AUSTRALIA IS THE PLATFORM FOR INTERNATIONAL SALES Commercialisation progress Next steps Established foothold Rapid customer acquisitions ― Secured relationships with top tier ― Targeting trials with large hospitals and clinical customers in NSW and Victoria labs in
Slide 15: Europe: strong progress on multiple fronts
2 Europe: strong progress on multiple fronts ACTIVELY INCREASING PROFILE IN PREPARATION FOR PRODUCT APPROVALS Commercialisation progress Next steps Distributors hired and evaluations underway Strategic market with large opportunity ― Currently adding to European team ― Europe has an addressable MDx
Slide 16: North America: accelerate direct sales approach
3 North America: accelerate direct sales approach FIRST ASR SALES AND PROGRESS TOWARD FDA CLEARANCE Commercialisation progress Next steps Increasing traction with ASR approach Largest market for MDx globally ― First ASR sales contract received with US ― Addressable market of approximately pathology
Slide 17: Clear path to global commercialisation for all products
Clear path to global commercialisation for all products Australia EU US Product Trials Pilot stage Registration Ready for Registration Ready for FDA trials Clearance Products development underway revenue2 and sales trials and sales ASR trials initiated and sales Existing EasyScreen™ 2018 2019 produc
Slide 18: FY19 goals
FY19 goals GSS IS WELL POSITIONED TO DELIVER ON ITS GLOBAL COMMERCIALISATION STRATEGY IN FY19 FY19 Regulatory CE / TGA Registration – Respiratory FDA Approvals – Enteric (expected in CY19) CE / TGA Registration – Flavivirus CE / TGA Registration – STI Commercialisation EU - Establish sales warehouse
Slide 19: US$1.2bn market opportunity for existing products
US$1.2bn market opportunity for 3 existing products ENTERIC RESPIRATORY STI Commercialisation underway with Significant growth opportunity Innovative STI detection kit testing full regulatory registration in with registration in Australia pathogens contracted by 1 million Europe received and Europe
Slide 20: Significant strategic interest in MDx technologies
Significant strategic interest in MDx technologies ▪ Major MDx players are pursuing aggressive acquisition strategies to secure emerging technologies − …and they are prepared to pay high multiples to secure opportunities EV/Revenue Date ↓ Target Acquirer Deal value (US$m) multiple (x) Target Descrip
Slide 21: Appendix
APPENDIX FURTHER INFORMATION ON 3BASETM TECHNOLOGY Genetic Signatures Limited Investor Presentation – August 2018
Slide 22: Product groups underpinned by 3base technology
7 product groups underpinned by 3baseTM technology Product group Target pathogens Key highlights Four EasyScreen™ 20+ enteric pathogens All tests have full regulatory registration in existing Enteric Includes Salmonella, C. difficile Bacteria, Europe (10-20x the size of Aus market) products Protozoa
Slide 23: Detection of infectious diseases
Detection of infectious diseases THERE IS POTENTIAL TO TRANSFORM THE MODERN MICROBIOLOGY LABORATORY AND THE CARE OF PATIENTS WITH SUSPECTED INFECTIONS Current process Industry problems Inefficient: window between specimen collection and organism identification is large and can: Traditional methods f
Slide 24: 3base reduces complexity by 94%
3baseTM reduces complexity by 94% SIGNIFICANT REDUCTION IN COMPLEXITY WHILE MAINTAINING OR INCREASING ACCURACY 3base™ showed superior performance in HPV clinical trial 20% improvement in homology Seq 1 4 base sequences GATGGCGATATGGTTGACAC 3base™ base sequences GATGGTGATATGGTTGATAT 94% reduction in
Slide 25: EasyScreen customers are strong advocates
EasyScreenTM customers are strong advocates “We use EasyScreenTM at ACL for its robust user Tony Field friendly automation, higher levels of specificity for Operations Manager clinical samples and our confidence in delivering Australian Clinical Labs clinically significant results to our clinicians.
Genetic Signatures — Investor Presentation (August 2018) on 6ix